Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Sells $1,405,047.12 in Stock

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) EVP Mark Neumann sold 18,714 shares of the firm’s stock in a transaction on Friday, August 16th. The stock was sold at an average price of $75.08, for a total value of $1,405,047.12. Following the completion of the sale, the executive vice president now directly owns 29,700 shares of the company’s stock, valued at $2,229,876. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Intra-Cellular Therapies Trading Up 1.7 %

Shares of Intra-Cellular Therapies stock traded up $1.26 during trading on Tuesday, hitting $76.99. The stock had a trading volume of 365,765 shares, compared to its average volume of 982,394. Intra-Cellular Therapies, Inc. has a 12 month low of $45.50 and a 12 month high of $84.89. The firm has a market cap of $8.13 billion, a price-to-earnings ratio of -65.46 and a beta of 1.01. The business’s 50-day moving average is $74.50 and its 200 day moving average is $70.95.

Intra-Cellular Therapies (NASDAQ:ITCI) last announced its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.03. Intra-Cellular Therapies had a negative net margin of 21.57% and a negative return on equity of 18.49%. The company had revenue of $161.40 million during the quarter, compared to analyst estimates of $157.74 million. During the same period in the previous year, the business earned ($0.45) earnings per share. The firm’s quarterly revenue was up 45.7% compared to the same quarter last year. As a group, equities analysts expect that Intra-Cellular Therapies, Inc. will post -0.54 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on ITCI shares. Canaccord Genuity Group lifted their price objective on Intra-Cellular Therapies from $107.00 to $113.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. JPMorgan Chase & Co. lifted their target price on shares of Intra-Cellular Therapies from $75.00 to $78.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 12th. Needham & Company LLC restated a “buy” rating and set a $100.00 price target on shares of Intra-Cellular Therapies in a research note on Wednesday, August 7th. UBS Group cut their price objective on shares of Intra-Cellular Therapies from $83.00 to $79.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Finally, Mizuho boosted their target price on shares of Intra-Cellular Therapies from $96.00 to $100.00 and gave the company a “buy” rating in a report on Friday, June 21st. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $96.73.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of ITCI. Oak Ridge Investments LLC purchased a new position in shares of Intra-Cellular Therapies in the second quarter worth $811,000. Perceptive Advisors LLC bought a new stake in shares of Intra-Cellular Therapies during the 4th quarter valued at $7,735,000. SG Americas Securities LLC boosted its stake in Intra-Cellular Therapies by 962.7% during the second quarter. SG Americas Securities LLC now owns 48,778 shares of the biopharmaceutical company’s stock worth $3,341,000 after acquiring an additional 44,188 shares in the last quarter. Schroder Investment Management Group lifted its holdings in shares of Intra-Cellular Therapies by 36.7% during the fourth quarter. Schroder Investment Management Group now owns 779,823 shares of the biopharmaceutical company’s stock valued at $55,851,000 after purchasing an additional 209,331 shares during the last quarter. Finally, Clearbridge Investments LLC boosted its holdings in Intra-Cellular Therapies by 12.3% in the first quarter. Clearbridge Investments LLC now owns 1,744,551 shares of the biopharmaceutical company’s stock worth $120,723,000 after acquiring an additional 191,416 shares in the last quarter. 92.33% of the stock is currently owned by institutional investors.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.